Introduction
Vajikarana has remained one of the major healthcare segments from yore, because this is said to enhance not only sexual performance, but also improves the quality of the off-springs. [1] The segment has become more important in the recent past, because the changing lifestyle is taking a toll on the status of male sexual health in the global population. The incidence of infertility, erectile dysfunction, subnormal desire and performance in sexual intercourse are increasing alarmingly.
Approximately 15-20 percent of all cohabiting couples are infertile. Up to 50 percent of these cases belong to male infertility, which means that nearly 7.5 to 10 percent of all men in the reproductive age group are infertile. Erectile dysfunction is said to afflict as much as 10 percent of the male population. [2] Conventional medicine has discovered few chemicals in this segment, but these agents are associated with many unwanted and serious adverse effects. Therefore, traditional medicines like Ayurveda and Chinese medicines have been the mainstay in this 
Materials and Methods

Study design
A randomized, double blind, placebo-controlled trial.
Study population
The study population was made up of apparently healthy and consenting male volunteers between 20 to 40 years of age, registered at the OPD of NIA, Jaipur. The study followed the concept of Vajikarana in Ayurveda, which stated that Vajikarana should be administered on a daily basis (Nitya) [10] to disease-free individuals (Kalya) during a young age (Udagra/Tarunavaya). [11] Thus, the age of the study population was stratified at 20-40 years. The total number of 30 volunteers were registered after taking due consent and were randomly assigned to two groups A and B.
Trial drug
Botanically authenticated dried root tubers of C. borivilianum were sourced from the cultivated fields at Shivagangai Farm of Century Agrotech Limited, Chennai. Water extract of the quality-assured samples was prepared and capsulated in soft-gelatin capsules of 500 mg each. Barley powder was encapsulated in similar capsules as placebo in the study dose, because it had practically no effect on semen and testosterone.
Dose, duration, and administration
The trial drug was given as capsules of 500 mg, twice daily, before food, with normal water, for 12 weeks. The volunteers were dispensed the required quantity of the trial drugs on every third week for better compliance.
Grouping of the volunteers
Registered and screened volunteers were randomly divided into two groups A (trial group) and B (placebo group). The trial drug and the placebo were sealed in plastic containers containing 180 capsules. These containers were coded by a person not related to the study. The coding documents were sealed and kept under safe custody. The envelope was opened after completion of the trial, to decode it for interpretation of the observations.
Volunteers Inclusion criteria
1. Apparently healthy male volunteers of age 20 to 40 years 2. Had not participated in a similar clinical investigation in the past 12 weeks 3. Was willing to give written informed consent and come for regular observation.
Volunteers exclusion criteria
1. Volunteers suffering from any organic disorder 2. Volunteers taking or likely to take steroid therapy 3. Volunteers taking other medicine for the same purpose.
Volunteers discontinuation/withdrawal criteria
• Any adverse/serious adverse event is encountered, where continuation of the study is a serious risk to the volunteer • Volunteers not complying with the protocol • Volunteers not turning up for assessment in time • Volunteers expressing a desire to withdraw.
Criteria of Assessment
The enrolled volunteers were assessed at baseline (day 0 visit), and then after the end of the trial, that is, the twelfth week of medication, for the following parameters:
Statistical method
The values of the above parameters were recorded before and after the treatment for both the groups and were analyzed by using the Student's paired 't' test.
Observation and Results
The values of various laboratory parameters of both the Groups A (CB) and B (Placebo) and their statistical analysis revealed the following observations [ 
Discussion
C. borivilianum is a popular drug, and its root tubers are used for improving male sexual health. The water extract of the plant has shown similar activity and has been found to be safe. The study aims to reaffirm the traditional claim that the extract of this plant improves male sexual health, by assessing its effect on semen and testosterone, which are the nearest equivalents of Shukradhatu.
The treated group showed a statistically highly significant improvement in all the assessed parameters of semen, whereas, the placebo group showed no significant improvement in these parameters. The treated group showed statistically significant improvement in serum testosterone, but in a lesser degree in comparison to the semen parameters.
The most significant changes were seen in the semen volume and sperm count, in comparison to sperm motility, indicating the greater selective role of the trial drug in these two parameters. The trial drug contains saponin and stigmasterol, which are hypothesized to stimulate the process of spermatogenesis and the mucilage present in the trial drug is supposed to have a role in increasing the volume of semen.
The trial drug did not exert such a significant effect on the serum testosterone level of the volunteers, although the improvements were better than in the placebo group. This could be due to the presence of normal levels of serum testosterone in almost all volunteers, leaving very little scope for improvement. Another trial involving subjects with diminished serum testosterone might clarify its activity, because C. borivilianum contains stigmasterol which hypothetically should have an effect on testosterone.
The absence of any adverse drug reactions (ADRs) suggests that C. borivilianum is a well-tolerated medicine in the trial dose and can be used for a longer duration.
Conclusion
The findings of the study prompt the authors to suggest that, Water extract of Chlorophytum borivilianum improves the quantity and quality of semen in a statistically significant manner in healthy male adults between 20 to 40 years of age, in comparison to the placebo, when used for 12 weeks, in a dose of 500 mg b.i.d. Water extract of Chlorophytum borivilianum does improve the serum testosterone level in a majority of volunteers in a trial dose, in comparison to the placebo, but a statistically significant effect was not observed. No volunteer developed any ADR, confirming its safety for human use. Therefore, the study corroborates the traditional claim that Chlorophytum borivilianum is a Shukraldravya, as it improves the semen and testosterone, the commonly accepted equivalents of Shukradhatu. 
